- Home
- YUMC vs UTHR Comparison
YUMC vs UTHR Comparison
Compare YUMC & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YUMC
- UTHR
- Stock Information
- Founded
- YUMC 1987
- UTHR 1996
- Country
- YUMC China
- UTHR United States
- Employees
- YUMC N/A
- UTHR N/A
- Industry
- YUMC Restaurants
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- YUMC Consumer Discretionary
- UTHR Health Care
- Exchange
- YUMC Nasdaq
- UTHR Nasdaq
- Market Cap
- YUMC 16.3B
- UTHR 14.4B
- IPO Year
- YUMC N/A
- UTHR 1999
- Fundamental
- Price
- YUMC $43.98
- UTHR $308.00
- Analyst Decision
- YUMC Buy
- UTHR Buy
- Analyst Count
- YUMC 2
- UTHR 12
- Target Price
- YUMC $48.70
- UTHR $392.00
- AVG Volume (30 Days)
- YUMC 3.4M
- UTHR 439.7K
- Earning Date
- YUMC 04-30-2025
- UTHR 04-30-2025
- Dividend Yield
- YUMC 2.18%
- UTHR N/A
- EPS Growth
- YUMC 19.63
- UTHR 18.86
- EPS
- YUMC 2.38
- UTHR 25.10
- Revenue
- YUMC $11,326,000,000.00
- UTHR $2,994,100,000.00
- Revenue This Year
- YUMC $7.59
- UTHR $11.45
- Revenue Next Year
- YUMC $6.83
- UTHR $6.11
- P/E Ratio
- YUMC $18.47
- UTHR $12.27
- Revenue Growth
- YUMC 2.79
- UTHR 19.84
- 52 Week Low
- YUMC $28.50
- UTHR $260.41
- 52 Week High
- YUMC $53.99
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- YUMC 43.64
- UTHR 57.25
- Support Level
- YUMC $43.04
- UTHR $290.02
- Resistance Level
- YUMC $44.26
- UTHR $319.40
- Average True Range (ATR)
- YUMC 1.13
- UTHR 10.02
- MACD
- YUMC 0.06
- UTHR 2.72
- Stochastic Oscillator
- YUMC 41.64
- UTHR 69.99
About YUMC Yum China Holdings Inc.
With more than 16,000 units and almost USD 12 billion in systemwide sales in 2024, Yum China is the largest restaurant operator in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (11,648 units) and Pizza Hut (3,724), but the company's portfolio also includes other brands such as Little Sheep, Taco Bell, Huang Ji Huang, and Lavazza (collectively representing more than 1,000 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.